| Prev Close | 14.42 |
| Open | 14.64 |
| Day Low/High | 14.57 / 14.84 |
| 52 Wk Low/High | 12.75 / 23.11 |
| Volume | 4.49M |
Mylan N.V. (MYL)
14.62
0.20
1.40
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 516.95B |
| Market Cap | 7.35B |
| P/E Ratio | 26.81 |
| Div & Yield | N.A. (N.A) |
Latest News
Uncertainty Reigns, Trading Tech Stocks, Don't Trust The Rally
Pull in timelines and focus on stocks that will ultimately do well in a post-Covid world.
The Virus Remains in Control, Unrealistic V-Shaped Recovery, Trading 2 Stocks
I do think the key to reopening this economy is one of greatly expanded testing for Covid-19, once a reliable treatment has made it past clinical testing, and into mass production.
Failed Rallies, Semiconductors Rising and the Fed's Big Guns
The Fed has attacked developing problems in real-time -- and as China shows signs of life, the semi stocks are benefitting.
I'm Adding This Pharma Company to My Top Stocks for 2020 List
Recro Pharma Inc., which makes drugs such as Ritalin LA for Novartis, looks healthy going into 2020.
Mylan Breaks Out on the Upside From a 9-Month Base Pattern
Let's drill down on the charts of this global healthcare company.
The Price of Fair Trade, Defense Stocks Volatility, Eyes on InMode: Market Recon
Investors must understand that the narrative around trade with China has evolved as the two sides work on a 'Phase One' mini-trade deal, but this is about much more than that.
The Week Ahead: Earnings Season Is Far From Over
Disney, Qualcomm and Square are among 75 key reports we are watching.
Jim Cramer: Here's Why the Market's So Feckless and Reactive
So many companies -- like Netflix, Facebook and Johnson & Johnson -- are not trading on earnings per share, but on factors that are nearly impossible to quantify.
While No Magic Pill, Mylan Deal Might Just Revive Drugmaker
The merger with Pfizer's off-patent branded medicines business may be a life-preserver for bulls and provide meaningful expansion across geographical regions while leveraging Pfizer's commercialization capabilities.
A Look at Mylan's New Post-Merger Management
What new management means for Mylan shareholders moving forward.
Mylan Will Bounce Today and Become Stronger on the Short-Term Charts
Pfizer is in talks to merge its off-patent drug operation with Mylan.
Mylan Jumps on Deal With Pfizer to Form New Company
Pfizer will combine its off-patent drug business with Mylan in the as-yet-to-be-named new company.
Pfizer Shares Rise Even as U.S. Lawmakers, Administration Criticize Drug Pricing
Shares of the New York City-based pharmaceutical giant are rising on Monday.
Mylan May Make Generics but Its Charts are Starting to Look 'Name Brand'
Let's check of the charts and indicators to see if this is a good time to approach the long side of MYL.
4 Scenarios That Will Impact the Market: Market Recon
And keep in mind that earnings season is not over, and there's enough juice left to impact the marketplace.
3 Small Biotech Stocks to Watch in the Fourth Quarter
These are just a few of the names I expect to do well to close out 2018.
3 Small Biotechs on My Q4 Watch List
These are a few of the names I expect to do well to close out 2018.
Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
How to Play Trump's New 'War' With Iran: Market Recon
While the move higher for crude prices late Tuesday took the energy sector with it, defense and aerospace names saw benefit as well.
